The inhalation characteristics of patients when they use different dry powder inhalers

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 28, Issue 1, 2015, Pages 35-42

  Azouz, Wahida ^a   Chetcuti, Philip ^b   Hosker, Harold S R ^c   Saralaya, Dinesh ^d   Stephenson, John ^a   Chrystyn, Henry ^a  

^a UNIVERSITY OF HUDDERSFIELD   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

^c AIREDALE GENERAL HOSPITAL   (United Kingdom)

^d BRADFORD ROYAL INFIRMARY   (United Kingdom)

Author keywords

asthma; COPD; dry powder inhalers; inhalation profiles; inhaled therapy

Indexed keywords

LACTOSE; PLACEBO; BRONCHODILATING AGENT; POWDER;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; CHILD; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE SEVERITY; DRY POWDER INHALER; FEMALE; FLOW RATE; HUMAN; INHALATION; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE; METERED DOSE INHALER; OPEN STUDY; PRESSURE; SPIROMETER; TURBULENT FLOW; AGE; COMPARATIVE STUDY; CONTROLLED STUDY; EQUIPMENT DESIGN; FORCED EXPIRATORY VOLUME; INHALATIONAL DRUG ADMINISTRATION; LUNG; MIDDLE AGED; PATHOPHYSIOLOGY; PEAK EXPIRATORY FLOW; POWDER; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; TASK PERFORMANCE; TIME; UNITED KINGDOM; VITAL CAPACITY; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGE FACTORS; ASTHMA; BRONCHODILATOR AGENTS; CHILD; CHILD, PRESCHOOL; DRY POWDER INHALERS; ENGLAND; EQUIPMENT DESIGN; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INHALATION; LUNG; MALE; MIDDLE AGED; PEAK EXPIRATORY FLOW RATE; POWDERS; PRESSURE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TASK PERFORMANCE AND ANALYSIS; TIME FACTORS; VITAL CAPACITY; YOUNG ADULT;

EID: 84922496602     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2013.1119     Document Type: Article

References (42)

1. Melani AS, Bonavia M, Cilenti V, Cinti C, Lodi M, Martucci P, Serra M, Scichilone N, Sestini P, Aliani M, Neri M; Gruppo Educazionale Associazione Italiana Pneumologi Ospedalieri: Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;105:930-938.
2. Clark AR, and Hollingworth AM: The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers-implications for in vitro testing. J Aerosol Med. 1993;6:99-110.
3. Borgstrom L: On the use of dry powder inhalers in situations perceived as constrained. J Aerosol Med. 2001;14: 281-287.
4. Newman SP, and Busse WW: Evolution of dry powder inhaler design, formulation, and performance. Respir Med. 2002;96:293-304.
5. Laube BL, Janssens HM, de Jongh FH, Devadason SG, Dhand R, Diot P, Everard ML, Horvath I, Navalesi P, Voshaar T, Chrystyn H; European Respiratory Society; International Society for Aerosols in Medicine: What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011;37:1308-1417.
6. Engel T, Scharling B, Skovsted B, and Heinig JH: Effects, side effects and plasma concentrations of terbutaline in adult asthmatics after inhaling from a dry powder inhaler device at different inhalation flows and volumes. Br J Clin Pharmacol. 1992;33:439-444.
7. Pedersen S, Hansen OR, and Fuglsang G: Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch Dis Child. 1990;65:308-310.
8. Nielsen KG, Skov M, Klug B, Ifversen M, and Bisgaard H: Flow-dependent effect of formoterol dry-powder inhaled from the Aerolizer. Eur Respir J. 1997;10:2105-2109.
9. Chrystyn H: Effects of device design on patient compliance: comparing the same drug in different devices. In: RN Dalby, PR Byron, J Peart, JD Suman, and PM Young, (eds). RDD Europe 2009. Davis Healthcare International, River Grove, IL; pp. 105-116, 2009.
10. Amirav I, Newhouse MT, and Mansour Y: Measurement of peak inspiratory flow with in-check dial device to simulate low-resistance (Diskus) and high-resistance (Turbohaler) dry powder inhalers in children with asthma. Pediatr Pulmonol. 2005;39:447-451.
11. Pedersen S: Inspiratory capacity through the Turbuhaler in various patient groups. J Aerosol Med. 1994;7(Suppl 1): S55-S58.
12. Broeders ME, Molema J, Hop WC, Vermue NA, and Folgering HT: The course of inhalation profiles during an exacerbation of obstructive lung disease. Respir Med. 2004;98:1173-1179.
13. Azouz W, and Chrystyn H: Clarifying the dilemmas about inhalation techniques for dry powder inhalers: integrating science with clinical practice. Prim Care Respir J. 2012;21: 208-213.
14. Everard ML, Devadason SG, and Le Souef PN: Flow early in the inspiratory manoeuvre affects the aerosol particle size distribution from a Turbuhaler. Respir Med. 1997;91: 624-628.
15. Kamin WE, Genz T, Roeder S, Scheuch G, Trammer T, Juenemann R, and Cloes RM: Mass output and particle size distribution of glucocorticosteroids emitted from different inhalation devices depending on various inspiratory parameters. J Aerosol Med. 2002;15:65-73.
16. Alaboud A, Assi KH, and Chrystyn H: In vitro characterization of the emitted dose from the foradil Aerolizer to identify the influence of inhalation flow, inhalation volume and the number of inhalations per dose. Respiratory Drug Delivery. 2012, 2010;3:803-806.
17. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, and King DR: Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14:902-907.
18. Global Initiative for Asthma (GINA), National Heart, Lung and Blood Institute, National Institutes of Health: GINA Report, Global Strategy for Asthma Management and Prevention, December, updated 2012. National Institutes of Health, Bethesda, MD. Available at www.ginasthma.com. Accessed April 2, 2014.
19. Global Initiative for Obstructive Lung Disease (GOLD), National Heart, Lung and Blood Institute, National Institutes of Health: GOLD Report, Global Strategy for Diagnosis, Management and Prevention of COPD, February 2013. National Institutes of Health, Bethesda, MD. Available from www.goldcopd.org. Accessed April 2, 2014.
20. Palander A, Mattila T, Karka M, and Muttonen E: In-vitro comparison of three salbutamol containing multidose dry powder inhalers. Clin Drug Invest. 2000;20:25-33.
21. Nadarassan DK, Assi KH, and Chrystyn H: Aerodynamic characteristics of a dry powder inhaler at low inhalation flows using a mixing inlet with an Andersen Cascade Impactor. Eur J Pharm Sci. 2010;39:348-354.
22. Nielsen KG, Auk IL, Bojsen K, Ifversen M, Klug B, and Bisgaard H: Clinical effect of Diskus dry-powder inhaler at low and high inspiratory flow-rates in asthmatic children. Eur Respir J. 1998;11:350-354.
23. Koskela T, Malmström K, Sairanen U, Peltola S, Keski-Karhu J, and Silvasti M: Efficacy of salbutamol via Easyhaler unaffected by low inspiratory flow. Respir Med. 2000;94:1229-1233.
24. Nsour WM, Alldred A, Corrado J, and Chrystyn H: Measurement of peak inhalation rates with an in-check meter to identify an elderly patient's ability to use a Turbuhaler. Respir Med. 2001;95:965-968.
25. Al-Showair RA, Pearson SB, and Chrystyn H: The potential of a 2Tone Trainer to help patients use their metereddose inhalers. Chest. 2007;131:1776-1782.
26. Hawksworth GM, James L, and Chrystyn H: Characterization of the inspiratory manoeuvre when asthmatics inhale through a Turbohaler pre- and post-counselling in a community pharmacy. Respir Med. 2000;94:501-504.
27. Agertoft L, and Pedersen S: Importance of training for correct Turbuhaler use in preschool children. Acta Paediatr. 1998;87:842-847.
28. Dewar MH, Jamieson A, McLean A, and Crompton GK: Peak inspiratory flow through Turbuhaler in chronic obstructive airways disease. Respir Med. 1999;93:342-344.
29. Broeders MEAC, Molama J, Hop WCJ, and Folgering HTM Inhalation profiles in asthma and COPD patients: reproducibility and effect of instruction. J Aerosol Med. 2003;16:131-141.
30. Derom E, Strandga°rden K, Schelfhout V, Borgström L, and Pauwels R: Lung deposition and efficacy of inhaled formoterol in patients with moderate to severe COPD. Respir Med. 2007;101:1931-1941.
31. Tarsin WY, Pearson SB, Assi KH, and Chrystyn H: Emitted dose estimates from Seretide Diskus and Symbicort Turbuhaler following inhalation by severe asthmatics. Int J Pharm. 2006;16:131-137.
32. Malmstrom K, Sorva R, and Silvasti M: Application and efficacy of the multi-dose powder inhaler, Easyhaler, in children with asthma. Pediatr Allergy Immunol. 1999;10:66-70.
33. Malmberg LP, RytiläP, Happonen P, and Haahtela T: Inspiratory flows through dry powder inhaler in chronic obstructive pulmonary disease: age and gender rather than severity matters. Int J Chron Obstruct Pulmon Dis. 2010;9:257-262.
34. Bronsky EA, Grossman J, Henis MJ, Gallo PP, Yegen U, Della Cioppa G, Kottakis J, and Mehra S: Inspiratory flow rates and volumes with the Aerolizer dry powder inhaler in asthmatic children and adults. Curr Med Res Opin. 2004; 20:131-137.
35. Weuthen T, Roeder S, Brand P, Müllinger B, and Scheuch G: In vitro testing of two formoterol dry powder inhalers at different flow rates. J Aerosol Med. 2002;15:297-303.
36. Melchor R, Biddiscombe MF, Mak VH, Short MD, and Spiro SG: Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction. Thorax. 1993;48:506-511.
37. Borgstrom L, Bondesson E, Morén F, Trofast E, and Newman SP: Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. Eur Respir J. 1994;7:69-73.
38. Borgstrom L: On the use of dry powder inhalers in situations perceived as constrained. J Aerosol Med. 2001;14: 281-287.
39. Broeders ME, Molema J, Vermue NA, and Folgering HT: Peak inspiratory flow rate and slope of the inhalation profiles in dry powder inhalers. Eur Respir J. 2001;18:780-783.
40. United States Pharmacopeia: Aerosols, nasal sprays, metered dose inhalers and dry powder inhalers. The United States Pharmacopeia 35 [and] the National Formulary 30; 2012. Available at www.uspnf.com/uspnf/login. Accessed February 18, 2014.
41. European Pharmacopeia: Preparations for inhalation: aerodynamic assessment of fine particles. European Pharmacopoeia. 7.6th edition 2012. Available at findpdf.net/documents/european-pharmacopoeia-7-0.html. Accessed February 18, 2014.
42. Olsson B, Borgström L, Lundbäck H, and Svensson M: Validation of a general in vitro approach for prediction of total lung deposition in healthy adults for pharmaceutical inhalation products. J Aerosol Med Pulm Drug Deliv. 2013;26:355-369.